You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The study will evaluate the emergence of biomarkers that are indicators for autoimmune diseases and assess these biomarkers in mild and moderate COVID-19 patients.
Scipher will use the proceeds to further commercialize PrismRA, a molecular test intended to guide treatment decisions for patients with rheumatoid arthritis.
The changes follow a strategic review and are part of the company's previously announced plans for growing its revenues and reducing costs.
Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.
The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.
In January a federal court unsealed a False Claims Act suit from an industry insider that alleges a Myriad subsidiary engaged in a fraudulent kickback scheme.
The firm said that it delivered 27,126 flagship Avise CTD tests, including Avise Lupus, during the recently completed quarter, a 13 percent year-over-year increase.
The combined company will have operations in California and Texas, and will provide onsite, rapid diagnostics with data analytics capabilities.
The alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.
The four kits are compatible with the i-Track automated analyzer for biotherapy monitoring, which received CE marking in late 2019.